Industry Research Reports

Home > Reports > Medical Care > Acute Intermittent Porphyria - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Acute Intermittent Porphyria - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-01-24

Pages: 86 Pages

Report ld: 2339320

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Acute intermittent porphyria (AIP) is a genetic metabolic disorder affecting the production of heme, the oxygen-binding prosthetic group of hemoglobin. It is characterized by a deficiency of the enzyme porphobilinogen deaminase.

The global market for Acute Intermittent Porphyria was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

North American market for Acute Intermittent Porphyria was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Acute Intermittent Porphyria was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Europe market for Acute Intermittent Porphyria was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global key companies of Acute Intermittent Porphyria include Dahaner, Roche, Bio-Rad Laboratories, Siemens, ARKRAY, Sysmex Corporation and ACON Laboratories, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Acute Intermittent Porphyria, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Acute Intermittent Porphyria by region & country, by Type, and by Application.

The Acute Intermittent Porphyria market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Intermittent Porphyria.

Market Segmentation

Report Metric
Details
Report Title
Acute Intermittent Porphyria - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global Acute Intermittent Porphyria Companies Covered
Dahaner, Roche, Bio-Rad Laboratories, Siemens, ARKRAY, Sysmex Corporation, ACON Laboratories
Global Acute Intermittent Porphyria Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acute Intermittent Porphyria Market, Segment by Type
Gonadotropin-Releasing Hormone Analogues

Prophylactic Hematin Infusions
Global Acute Intermittent Porphyria Market, Segment by Application
Hospitals & Clinics

Research Centers
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Acute Intermittent Porphyria manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Acute Intermittent Porphyria in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Acute Intermittent Porphyria in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Acute Intermittent Porphyria Product Introduction
    1.2 Global Acute Intermittent Porphyria Market Size Forecast
    1.3 Acute Intermittent Porphyria Market Trends & Drivers
        1.3.1 Acute Intermittent Porphyria Industry Trends
        1.3.2 Acute Intermittent Porphyria Market Drivers & Opportunity
        1.3.3 Acute Intermittent Porphyria Market Challenges
        1.3.4 Acute Intermittent Porphyria Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Acute Intermittent Porphyria Players Revenue Ranking (2023)
    2.2 Global Acute Intermittent Porphyria Revenue by Company (2019-2024)
    2.3 Key Companies Acute Intermittent Porphyria Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Acute Intermittent Porphyria Product Offered
    2.5 Key Companies Time to Begin Mass Production of Acute Intermittent Porphyria
    2.6 Acute Intermittent Porphyria Market Competitive Analysis
        2.6.1 Acute Intermittent Porphyria Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Acute Intermittent Porphyria Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Intermittent Porphyria as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Gonadotropin-Releasing Hormone Analogues
        3.1.2 Prophylactic Hematin Infusions
    3.2 Global Acute Intermittent Porphyria Sales Value by Type
        3.2.1 Global Acute Intermittent Porphyria Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Acute Intermittent Porphyria Sales Value, by Type (2019-2030)
        3.2.3 Global Acute Intermittent Porphyria Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Hospitals & Clinics
        4.1.2 Research Centers
    4.2 Global Acute Intermittent Porphyria Sales Value by Application
        4.2.1 Global Acute Intermittent Porphyria Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Acute Intermittent Porphyria Sales Value, by Application (2019-2030)
        4.2.3 Global Acute Intermittent Porphyria Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Acute Intermittent Porphyria Sales Value by Region
        5.1.1 Global Acute Intermittent Porphyria Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Acute Intermittent Porphyria Sales Value by Region (2019-2024)
        5.1.3 Global Acute Intermittent Porphyria Sales Value by Region (2025-2030)
        5.1.4 Global Acute Intermittent Porphyria Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Acute Intermittent Porphyria Sales Value, 2019-2030
        5.2.2 North America Acute Intermittent Porphyria Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Acute Intermittent Porphyria Sales Value, 2019-2030
        5.3.2 Europe Acute Intermittent Porphyria Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Acute Intermittent Porphyria Sales Value, 2019-2030
        5.4.2 Asia Pacific Acute Intermittent Porphyria Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Acute Intermittent Porphyria Sales Value, 2019-2030
        5.5.2 South America Acute Intermittent Porphyria Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Acute Intermittent Porphyria Sales Value, 2019-2030
        5.6.2 Middle East & Africa Acute Intermittent Porphyria Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Acute Intermittent Porphyria Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Acute Intermittent Porphyria Sales Value
    6.3 United States
        6.3.1 United States Acute Intermittent Porphyria Sales Value, 2019-2030
        6.3.2 United States Acute Intermittent Porphyria Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Acute Intermittent Porphyria Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Acute Intermittent Porphyria Sales Value, 2019-2030
        6.4.2 Europe Acute Intermittent Porphyria Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Acute Intermittent Porphyria Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Acute Intermittent Porphyria Sales Value, 2019-2030
        6.5.2 China Acute Intermittent Porphyria Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Acute Intermittent Porphyria Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Acute Intermittent Porphyria Sales Value, 2019-2030
        6.6.2 Japan Acute Intermittent Porphyria Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Acute Intermittent Porphyria Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Acute Intermittent Porphyria Sales Value, 2019-2030
        6.7.2 South Korea Acute Intermittent Porphyria Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Acute Intermittent Porphyria Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Acute Intermittent Porphyria Sales Value, 2019-2030
        6.8.2 Southeast Asia Acute Intermittent Porphyria Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Acute Intermittent Porphyria Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Acute Intermittent Porphyria Sales Value, 2019-2030
        6.9.2 India Acute Intermittent Porphyria Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Acute Intermittent Porphyria Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Dahaner
        7.1.1 Dahaner Profile
        7.1.2 Dahaner Main Business
        7.1.3 Dahaner Acute Intermittent Porphyria Products, Services and Solutions
        7.1.4 Dahaner Acute Intermittent Porphyria Revenue (US$ Million) & (2019-2024)
        7.1.5 Dahaner Recent Developments
    7.2 Roche
        7.2.1 Roche Profile
        7.2.2 Roche Main Business
        7.2.3 Roche Acute Intermittent Porphyria Products, Services and Solutions
        7.2.4 Roche Acute Intermittent Porphyria Revenue (US$ Million) & (2019-2024)
        7.2.5 Roche Recent Developments
    7.3 Bio-Rad Laboratories
        7.3.1 Bio-Rad Laboratories Profile
        7.3.2 Bio-Rad Laboratories Main Business
        7.3.3 Bio-Rad Laboratories Acute Intermittent Porphyria Products, Services and Solutions
        7.3.4 Bio-Rad Laboratories Acute Intermittent Porphyria Revenue (US$ Million) & (2019-2024)
        7.3.5 Siemens Recent Developments
    7.4 Siemens
        7.4.1 Siemens Profile
        7.4.2 Siemens Main Business
        7.4.3 Siemens Acute Intermittent Porphyria Products, Services and Solutions
        7.4.4 Siemens Acute Intermittent Porphyria Revenue (US$ Million) & (2019-2024)
        7.4.5 Siemens Recent Developments
    7.5 ARKRAY
        7.5.1 ARKRAY Profile
        7.5.2 ARKRAY Main Business
        7.5.3 ARKRAY Acute Intermittent Porphyria Products, Services and Solutions
        7.5.4 ARKRAY Acute Intermittent Porphyria Revenue (US$ Million) & (2019-2024)
        7.5.5 ARKRAY Recent Developments
    7.6 Sysmex Corporation
        7.6.1 Sysmex Corporation Profile
        7.6.2 Sysmex Corporation Main Business
        7.6.3 Sysmex Corporation Acute Intermittent Porphyria Products, Services and Solutions
        7.6.4 Sysmex Corporation Acute Intermittent Porphyria Revenue (US$ Million) & (2019-2024)
        7.6.5 Sysmex Corporation Recent Developments
    7.7 ACON Laboratories
        7.7.1 ACON Laboratories Profile
        7.7.2 ACON Laboratories Main Business
        7.7.3 ACON Laboratories Acute Intermittent Porphyria Products, Services and Solutions
        7.7.4 ACON Laboratories Acute Intermittent Porphyria Revenue (US$ Million) & (2019-2024)
        7.7.5 ACON Laboratories Recent Developments

 8 Industry Chain Analysis
    8.1 Acute Intermittent Porphyria Industrial Chain
    8.2 Acute Intermittent Porphyria Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Acute Intermittent Porphyria Sales Model
        8.5.2 Sales Channel
        8.5.3 Acute Intermittent Porphyria Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Acute Intermittent Porphyria Market Trends
    Table 2. Acute Intermittent Porphyria Market Drivers & Opportunity
    Table 3. Acute Intermittent Porphyria Market Challenges
    Table 4. Acute Intermittent Porphyria Market Restraints
    Table 5. Global Acute Intermittent Porphyria Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Acute Intermittent Porphyria Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Acute Intermittent Porphyria Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Acute Intermittent Porphyria Product Type
    Table 9. Key Companies Time to Begin Mass Production of Acute Intermittent Porphyria
    Table 10. Global Acute Intermittent Porphyria Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Intermittent Porphyria as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Acute Intermittent Porphyria Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Acute Intermittent Porphyria Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Acute Intermittent Porphyria Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Acute Intermittent Porphyria Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Acute Intermittent Porphyria Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Acute Intermittent Porphyria Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Acute Intermittent Porphyria Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Acute Intermittent Porphyria Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Acute Intermittent Porphyria Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Acute Intermittent Porphyria Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Acute Intermittent Porphyria Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Acute Intermittent Porphyria Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Acute Intermittent Porphyria Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Acute Intermittent Porphyria Sales Value by Region (2019-2024) & (%)
    Table 27. Global Acute Intermittent Porphyria Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Acute Intermittent Porphyria Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Acute Intermittent Porphyria Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Acute Intermittent Porphyria Sales Value, (2025-2030) & (US$ Million)
    Table 31. Dahaner Basic Information List
    Table 32. Dahaner Description and Business Overview
    Table 33. Dahaner Acute Intermittent Porphyria Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Acute Intermittent Porphyria Business of Dahaner (2019-2024)
    Table 35. Dahaner Recent Developments
    Table 36. Roche Basic Information List
    Table 37. Roche Description and Business Overview
    Table 38. Roche Acute Intermittent Porphyria Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Acute Intermittent Porphyria Business of Roche (2019-2024)
    Table 40. Roche Recent Developments
    Table 41. Bio-Rad Laboratories Basic Information List
    Table 42. Bio-Rad Laboratories Description and Business Overview
    Table 43. Bio-Rad Laboratories Acute Intermittent Porphyria Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Acute Intermittent Porphyria Business of Bio-Rad Laboratories (2019-2024)
    Table 45. Bio-Rad Laboratories Recent Developments
    Table 46. Siemens Basic Information List
    Table 47. Siemens Description and Business Overview
    Table 48. Siemens Acute Intermittent Porphyria Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Acute Intermittent Porphyria Business of Siemens (2019-2024)
    Table 50. Siemens Recent Developments
    Table 51. ARKRAY Basic Information List
    Table 52. ARKRAY Description and Business Overview
    Table 53. ARKRAY Acute Intermittent Porphyria Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Acute Intermittent Porphyria Business of ARKRAY (2019-2024)
    Table 55. ARKRAY Recent Developments
    Table 56. Sysmex Corporation Basic Information List
    Table 57. Sysmex Corporation Description and Business Overview
    Table 58. Sysmex Corporation Acute Intermittent Porphyria Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Acute Intermittent Porphyria Business of Sysmex Corporation (2019-2024)
    Table 60. Sysmex Corporation Recent Developments
    Table 61. ACON Laboratories Basic Information List
    Table 62. ACON Laboratories Description and Business Overview
    Table 63. ACON Laboratories Acute Intermittent Porphyria Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Acute Intermittent Porphyria Business of ACON Laboratories (2019-2024)
    Table 65. ACON Laboratories Recent Developments
    Table 66. Key Raw Materials Lists
    Table 67. Raw Materials Key Suppliers Lists
    Table 68. Acute Intermittent Porphyria Downstream Customers
    Table 69. Acute Intermittent Porphyria Distributors List
    Table 70. Research Programs/Design for This Report
    Table 71. Key Data Information from Secondary Sources
    Table 72. Key Data Information from Primary Sources
    Table 73. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Acute Intermittent Porphyria Product Picture
    Figure 2. Global Acute Intermittent Porphyria Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Acute Intermittent Porphyria Sales Value (2019-2030) & (US$ Million)
    Figure 4. Acute Intermittent Porphyria Report Years Considered
    Figure 5. Global Acute Intermittent Porphyria Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Acute Intermittent Porphyria Revenue in 2023
    Figure 7. Acute Intermittent Porphyria Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Gonadotropin-Releasing Hormone Analogues Picture
    Figure 9. Prophylactic Hematin Infusions Picture
    Figure 10. Global Acute Intermittent Porphyria Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 11. Global Acute Intermittent Porphyria Sales Value Market Share by Type, 2023 & 2030
    Figure 12. Product Picture of Hospitals & Clinics
    Figure 13. Product Picture of Research Centers
    Figure 14. Global Acute Intermittent Porphyria Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 15. Global Acute Intermittent Porphyria Sales Value Market Share by Application, 2023 & 2030
    Figure 16. North America Acute Intermittent Porphyria Sales Value (2019-2030) & (US$ Million)
    Figure 17. North America Acute Intermittent Porphyria Sales Value by Country (%), 2023 VS 2030
    Figure 18. Europe Acute Intermittent Porphyria Sales Value (2019-2030) & (US$ Million)
    Figure 19. Europe Acute Intermittent Porphyria Sales Value by Country (%), 2023 VS 2030
    Figure 20. Asia Pacific Acute Intermittent Porphyria Sales Value (2019-2030) & (US$ Million)
    Figure 21. Asia Pacific Acute Intermittent Porphyria Sales Value by Country (%), 2023 VS 2030
    Figure 22. South America Acute Intermittent Porphyria Sales Value (2019-2030) & (US$ Million)
    Figure 23. South America Acute Intermittent Porphyria Sales Value by Country (%), 2023 VS 2030
    Figure 24. Middle East & Africa Acute Intermittent Porphyria Sales Value (2019-2030) & (US$ Million)
    Figure 25. Middle East & Africa Acute Intermittent Porphyria Sales Value by Country (%), 2023 VS 2030
    Figure 26. Key Countries/Regions Acute Intermittent Porphyria Sales Value (%), (2019-2030)
    Figure 27. United States Acute Intermittent Porphyria Sales Value, (2019-2030) & (US$ Million)
    Figure 28. United States Acute Intermittent Porphyria Sales Value by Type (%), 2023 VS 2030
    Figure 29. United States Acute Intermittent Porphyria Sales Value by Application (%), 2023 VS 2030
    Figure 30. Europe Acute Intermittent Porphyria Sales Value, (2019-2030) & (US$ Million)
    Figure 31. Europe Acute Intermittent Porphyria Sales Value by Type (%), 2023 VS 2030
    Figure 32. Europe Acute Intermittent Porphyria Sales Value by Application (%), 2023 VS 2030
    Figure 33. China Acute Intermittent Porphyria Sales Value, (2019-2030) & (US$ Million)
    Figure 34. China Acute Intermittent Porphyria Sales Value by Type (%), 2023 VS 2030
    Figure 35. China Acute Intermittent Porphyria Sales Value by Application (%), 2023 VS 2030
    Figure 36. Japan Acute Intermittent Porphyria Sales Value, (2019-2030) & (US$ Million)
    Figure 37. Japan Acute Intermittent Porphyria Sales Value by Type (%), 2023 VS 2030
    Figure 38. Japan Acute Intermittent Porphyria Sales Value by Application (%), 2023 VS 2030
    Figure 39. South Korea Acute Intermittent Porphyria Sales Value, (2019-2030) & (US$ Million)
    Figure 40. South Korea Acute Intermittent Porphyria Sales Value by Type (%), 2023 VS 2030
    Figure 41. South Korea Acute Intermittent Porphyria Sales Value by Application (%), 2023 VS 2030
    Figure 42. Southeast Asia Acute Intermittent Porphyria Sales Value, (2019-2030) & (US$ Million)
    Figure 43. Southeast Asia Acute Intermittent Porphyria Sales Value by Type (%), 2023 VS 2030
    Figure 44. Southeast Asia Acute Intermittent Porphyria Sales Value by Application (%), 2023 VS 2030
    Figure 45. India Acute Intermittent Porphyria Sales Value, (2019-2030) & (US$ Million)
    Figure 46. India Acute Intermittent Porphyria Sales Value by Type (%), 2023 VS 2030
    Figure 47. India Acute Intermittent Porphyria Sales Value by Application (%), 2023 VS 2030
    Figure 48. Acute Intermittent Porphyria Industrial Chain
    Figure 49. Acute Intermittent Porphyria Manufacturing Cost Structure
    Figure 50. Channels of Distribution (Direct Sales, and Distribution)
    Figure 51. Bottom-up and Top-down Approaches for This Report
    Figure 52. Data Triangulation

Description

Acute intermittent porphyria (AIP) is a genetic metabolic disorder affecting the production of heme, the oxygen-binding prosthetic group of hemoglobin. It is characterized by a deficiency of the enzyme porphobilinogen deaminase.

The global market for Acute Intermittent Porphyria was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

North American market for Acute Intermittent Porphyria was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Acute Intermittent Porphyria was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Europe market for Acute Intermittent Porphyria was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global key companies of Acute Intermittent Porphyria include Dahaner, Roche, Bio-Rad Laboratories, Siemens, ARKRAY, Sysmex Corporation and ACON Laboratories, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Acute Intermittent Porphyria, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Acute Intermittent Porphyria by region & country, by Type, and by Application.

The Acute Intermittent Porphyria market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Intermittent Porphyria.

Market Segmentation